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Simple Summary: The efficacy of the local consolidative therapy in lung cancer has been reported
previously, however, those studies described the utility of the radiation therapy rather than of surgery.
Furthermore, those studies included either no or few patients with oncogene-driven NSCLC, which
has distinct biological properties and treatment options. Surgery is the most reliable method of
tumor removal that allows detailed examinations of resected tissue, such as comprehensive genetic
analysis. This retrospective study for the first time reports the operative outcomes and the benefit
of cytoreductive surgery in TKI-treated cases of oncogene-driven locally advanced or metastatic
NSCLC in parallel with the genetic analysis of the tumor.
Abstract: Most patients with oncogene-driven advanced non-small cell lung cancer (NSCLC) demon-
strate recurrence because of the developing targeted therapy resistance. In this retrospective study,
we assessed the efficacy of surgical local consolidative treatment by analyzing the operative outcomes
and genetic data in 44 patients who underwent pulmonary resection for stage IIIB/C–IV NSCLC
after targeted therapy. The initial mutations were in the EGFR (n = 32), ALK (n = 11), and ROS1
(n = 1) genes. The median interval from the initiation of tyrosine kinase inhibitor (TKI) therapy
immediately before the surgery to the actual operation was 9.8 months. Operative mortality was
absent. Four patients showed complete remission. The median follow-up period after TKI therapy
initiation was 23.1 months. The Kaplan–Meier survival analysis showed that the 2-year failure-free
survival and overall survival rates from the initiation of TKI were 70.8% and 95.0%, respectively.
During the follow-up period, two patients died and 15 suffered from disease progression. Among
the 32 patients with EGFR mutations, 12 showed additional mutations, and targeted agents were
replaced in nine patients after the operation. We conclude that pulmonary resection for advanced
NSCLC after targeted therapy is feasible, and the surgical specimens could be used for planning
further targeted therapy.
Keywords: advanced lung cancer; cytoreductive surgery; local consolidation; oncogenic-driven;
oligometastasis
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1. Introduction
Agents targeting proteins encoded by mutated EGFR, ALK, and ROS1 genes signif-
icantly improve the prognosis of advanced oncogene-driven non-small cell lung cancer
(NSCLC) [1,2]. Nonetheless, most patients eventually experience disease progression
because of the developing resistance to such targeted agents [3]. Approximately 60%
of patients develop first disease progression at the primary cancer sites [4,5]. Therefore,
following the initial response to targeted treatment, local consolidative therapy aimed at
the residual disease could potentially overcome the resistance and improve survival.
Randomized trials have provided evidence that this strategy could be effective in
advanced lung cancer [6–8]. In oligometastatic NSCLC, randomized studies have shown
that local consolidative therapy leads to higher progression-free (PFS) and overall survival
(OS) benefits compared with those afforded by either maintenance therapy or observation.
However, these studies included either no or few patients with oncogene-driven NSCLC,
which has distinct biological properties and treatment options. A recent phase II study of
residual metabolic disease showed that local ablative therapy after treatment with targeted
agents leads to better PFS [9]. However, that study had few patients and, as in previous
studies, radiation therapy was chosen as local consolidative therapy rather than surgery.
Intratumoral heterogeneity, tumor cell evolution after targeted therapy, and pharmacoki-
netic failure are the predominant causes of unsuccessful treatment outcome [10,11]. Surgery
is the most reliable method of tumor removal that allows detailed examination of resected
tissue, such as comprehensive genetic analysis and cytological tests. However, many important
questions must be addressed before proceeding to further prospective studies. In particular,
the safety of surgery in the local consolidation setting has to be prioritized.
Here, we assessed the operative outcomes of cytoreductive surgery with local consol-
idative purpose and genetic information of surgical specimens in patients with oncogene-
driven advanced NSCLC after targeted therapy.
2. Patients and Methods
2.1. Patients
This study was a retrospective review of a prospective lung cancer database at our
institution, using data collected between March 2018 and July 2020. The study was re-
viewed and approved by the Institutional Review Board of the Yonsei University College of
Medicine (IRB No. 4-2020-1227). The inclusion criteria required patients to have the follow-
ing: (1) histologically proven oncogene-driven NSCLC; (2) stage IIIB, IIIC, or IV advanced
NSCLC; and (3) to have undergone surgical resection as a form of local consolidative
therapy after treatment with tyrosine kinase inhibitors (TKIs).
Indication of operation was decided at a meeting of a multidisciplinary team that
consisted of thoracic surgeons, medical oncologists, pulmonologists, radiologists, and
radiation oncologists. We selected patients with good performance status (ECOG 0 to 1),
medically fit patients without problems that might increase the risk of surgery, and patients
with no or stable remnant metastatic lesions or those treated with other local consolidative
therapy for the remaining lesions after surgery. Patients were classified into two subgroups
based on the intent of surgery, one with residual lesions and the other with progressive
lesions after TKI therapy started immediately before the surgery.
We performed anatomic resection with complete mediastinal lymph node dissection
in most patients. Some patients underwent limited resection, depending on the situation
during surgery. In patients with cervical or abdominal lymph node metastasis, the lymph
node dissection at those areas was conducted concomitantly. TKI therapy was continued
in perioperative periods. The complications were graded based on the Clavien–Dindo
classification [12]. After the operation, the patients were followed up using chest and
abdomen computed tomography every 4 months for detecting the recurrence.
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2.2. Molecular Analyses
To detect EGFR mutations, peptide nucleic acid-mediated real-time PCR was per-
formed using the PANA Mutyper EGFR Kit (PANAGENE, Daejeon, Korea). To identify
ALK rearrangements, the VENTANA ALK (D5F3) CDx Assay (Ventana Medical Systems,
Tucson, AZ, USA) was performed. ROS1 rearrangements were detected with real-time PCR
using the ROS1 Gene Fusions Detection Kit (AmoyDx, Xiamen, China). Their detection
was also possible by next-generation sequencing, which will be described as follows.
2.3. Next-Generation Sequencing (NGS)
Targeted DNA sequencing was performed using TruSight™ Oncology 500 (Illumina,
San Diego, CA, USA). The TruSight™ Oncology 500 DNA panel was designed to detect
523 cancer-related genes with potential single nucleotide variants and indels, as well as
59 genes with potential amplifications. Briefly, 40 ng of formalin-fixed paraffin-embedded
(FFPE) tissue-derived DNA was extracted using the QIAGEN AllPrep FFPE Kit (Qiagen,
Hilden, Germany). After hybridization capture-based target enrichment, paired-end se-
quencing (2 × 150 bp) was performed using a NextSeq sequencer (Illumina). Variants with
a total depth of at least 100× and variant allele frequency of at least 1% were included for
analysis. Variant interpretation was based on the recommendations of the Association for
Molecular Pathology, American Society of Clinical Oncology, and College of American
Pathologists [13]. Actionable genetic alterations were stratified into one of the four levels
based on the OncoKB website (http://www.OncoKB.org, accessed 1 November 2020).
2.4. Statistical Analysis
Descriptive statistics were used to illustrate patient characteristics and outcomes.
Categorical variables are presented as frequencies and percentages; continuous variables
are expressed as the median with the range or interquartile range (IQR). Student’s t-test and
Mann–Whitney test, depending on the normality of distribution, and the χ2 test or Fisher’s
exact test were used to compare continuous and categorical variables, respectively. Based
on the criteria proposed by Travis et al. [14], MPR (major pathologic response) is defined
historically as 10% or less residual viable tumor following preoperative treatment, and
CR (complete pathologic response) is defined as no viable tumor following preoperative
treatment. Treatment failure-free survival (FFS) duration was defined as the time from
the initiation of TKI therapy immediately before the surgery to the earliest occurrence of
disease progression, end of treatment because of adverse events, or death. The duration of
PFS was defined as the time from surgery to disease progression or death from any cause.
The duration of OS was defined as the time from the initiation of TKI therapy immediately
before the surgery to death from any cause. Patients lost to follow-up were censored at the
time of the last contact. Actuarial survival curves were estimated using the Kaplan–Meier
method. Analyses were performed using SPSS version 25.0 (IBM Corporation, Somers, NY,
USA) and R software (version 4.0.3) with the “survival” and “ComplexHeatmap” packages
(R Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1. Baseline Characteristics and Treatments Prior to Surgery
From March 2018 to July 2020, 44 patients received pulmonary resection and me-
diastinal lymph node dissection for stage III B–C or IV A–B NSCLC after TKI therapy
(Table 1). The median age of patients was 59 years (range: 28–75 years), and 15 patients
(34.1%) were males. The initial stages were IIIB (n = 4), IIIC (n = 1), IVA (n = 15), and IVB
(n = 24). The initial metastasis sites were the brain (n = 10), bone (n = 6), lymph nodes
(n = 6), intrathoracic organs (n = 5), and multiple organs (n = 17). At the time of diagnosis,
22 patients (50%) had combined brain metastasis. The initial mutations were in the EGFR
(n = 32), ALK (n = 11), and ROS1 (n = 1) genes.
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Table 1. Patient characteristics.
Characteristic N or Median % or IQR





Never smoked 31 70.5%
Former smoker 12 27.3%
Current smoker 1 2.3%





FEV1, L 2.27 2.0–2.7
FEV1, % predicted 92.0% 83.5–101.0%
DLCO, mL/mmHg/min 17.1 15.4–19.6












Metastasis sites at diagnosis
Brain 10 22.7%
Bone 6 13.6%
Lymph nodes 6 13.6%
Intrathoracic organs 5 11.4%
Multiple organs 17 38.6%





Combined brain metastasis at diagnosis 22 50.00%
Mutational profile at diagnosis
EGFR mutation 32 72.7%
ALK fusion 11 25.0%
ROS1 fusion 1 2.3%
a as per the 8th edition of the TNM classification of lung cancer.
The preoperative disease status and treatment of these patients are presented in Table 2.
The median interval from the initiation of TKI therapy immediately before surgery
to actual operation was 9.8 months (range: 2.2–25.4 months). In regard to best responses,
41 patients (93.2%) had partial response, and three patients (6.8%) had stable disease
after the commencement of TKI therapy immediately before surgery according to RECIST
criteria [15]. Among them, eight and two patients showed disease progression in the
primary site and metastatic sites, respectively. Among the 32 patients with EGFR mutations,
15 patients underwent surgery during gefitinib treatment. Of the 12 patients treated with
osimertinib before surgery, six received it as their palliative first-line therapy and the other
six had it as their second-line therapy based on the acquired T790M mutation. In patients
treated with the later line osimertinib, the first-line treatments were afatinib (n = 3), gefitinib
(n = 1), erlotinib (n = 1), and AZD3759 (n = 1). In the 11 ALK-positive patients, the most
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common regimen before surgery was alectinib (n = 7), including five first-line alectinib
cases. The treatment courses of individual patients are shown in Figure 1.
Table 2. Preoperative disease status and treatment.
Variables N or Median % or IQR
Interval from the diagnosis to operation, months 10.9 8.5–18.2
Interval from the initiation of TKI immediately before






- First-line 6 13.6%
- Later-line based on the acquired T790M mutation 6 13.6%
Alectinib 7 15.9%
- First-line 5 11.4%
- Later-line 2 4.5%
Crizotinib 4 9.1%
Lorlatinib 1 2.3%
Best response to TKI immediately before surgery
Partial response 41 93.2%
Stable disease 3 6.8%
Preoperative local control for metastatic site 21 47.7%
Surgery 4 9.1%
- Brain 3 6.8%
- Lymph node 1 2.3%
Radiation therapy 15 34.1%
- Brain 8 18.2%
- Bone 5 11.4%
- Brain and bone 2 4.5%
Surgery with radiation therapy 2 4.5%
- Brain 2 4.5%





Preoperative primary lesion status
Partial response 6 13.6%
Stable disease 30 68.2%
Progressive disease 8 18.2%
Preoperative metastatic lesion status
Radiologic “No-evidence-of-disease” status 19 43.2%
Partial response 2 4.5%
Stable disease 21 47.7%
Progressive disease 2 4.5%
Intent of surgery
Residual lesions 34 77.3%
Progressive lesions 10 22.7%
In 21 patients (47.7%), other metastatic lesions were treated with surgery (n = 4,
9.1%), radiation therapy (n = 15, 34.1%), or a combination thereof (n = 2, 4.5%) prior
to pulmonary resection. At the primary lesion, 6 patients (13.6%) had partial response,
30 (68.2%) presented with stable disease, and 8 (18.2%) experienced disease progression.
At the metastatic site, 19 patients (43.2%) had no radiologic evidence of disease, 2 (4.5%)
had partial response, 21 (47.7%) had stable disease, and 2 (4.5%) experienced disease
progression. Of the two patients with disease progression in the metastatic lesion, one
underwent additional wedge resection of the metastatic lung lesion during surgery, whereas
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the other patient underwent additional radiation therapy of the metastatic bone lesion after
surgery. Thirty-four patients (77.3%) received surgery for their residual lesion, whereas
10 patients (22.7%) had it for their progressive lesion.
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3.2. Surgical Outcomes
The operative outcomes are shown in Table 3.
Table 3. Operative Outcomes.
Variables N or Median % or IQR
Extent of pulmonary resection






Conversion to thoracotomy 5 11.4%
- Difficult to dissect lymph node 3 6.8%
- Difficult to dissect pulmonary artery 2 4.5%
Combined surgical procedure 20 45.5%
Neck lymph node dissection 7 15.9%
Abdominal lymph node dissection 1 2.3%
Separate pulmonary wedge resection 4 9.1%
En-bloc resection of adjacent lobe 5 11.4%
Other procedure 3 6.8%
Duration of surgery, min 108.5 92.0–136.3
Duration of anesthesia, min 160.0 135.0–191.3
Estimated blood loss, mL
Minimal (≤50) 29 65.9%
50–200 12 27.3%
>200 3 6.8%




Intensive care unit stay (duration) 1 (1 day) 2.3%
Chest tube duration, days 4 3.0–5.3
Postoperative hospital stays, days 5 4.0–7.3
Complication (all) 15 34.1%
Prolonged air leak (>5 days) 5 11.4%
Chyle leakage 3 6.8%
Vocal cord palsies 2 4.5%
Bronchopleural fistula 1 2.3%
Acute kidney injury 1 2.3%
Acute lung injury 1 2.3%
Pneumonia 1 2.3%
Pneumothorax 1 2.3%
Complication (Clavien–Dindo > Gr 3) 4 9.1%
Chyle leakage 1 2.3%
Vocal cord palsies 1 2.3%
Broncho-pleural fistula 1 2.3%
Pneumothorax 1 2.3%
In-hospital mortality 0 0.0%
Lobectomy was performed in 37 patients (84.1%), sub-lobar resection in 5 patients
(11.4%), and bi-lobectomy in 2 patients (4.5%). The surgical approaches were video-assisted
thoracoscopic surgery (VATS) (n = 37, 84.1%), thoracotomy (n = 2, 4.5%), and conversion to
thoracotomy from VATS (n = 5; 11.4%). The reason for the conversion was the difficulty
of dissecting anthracosis or fibrotic lymph nodes between the bronchus and pulmonary
artery. Two of these were accompanied by pulmonary artery injury during dissection. The
following combined surgical procedures were performed in 20 patients: cervical lymph
node dissection (n = 7, 15.9%), abdominal lymph node dissection (n = 1, 2.3%), additional
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pulmonary wedge resection (n = 4, 9.1%), en-bloc resection of the adjacent lobe (n = 5,
11.4%), pericardial biopsy (n = 1, 2.3%), pleural biopsy (n = 1, 2.3%), and total thyroidectomy
with central neck node dissection for concomitant thyroid cancer (n = 1, 2.3%). The median
operation time was 108.5 min (range: 67–308 min). Most of the patients (n = 41, 93.2%)
had a relatively small blood loss of less than 200 mL, and only three patients (6.8%) lost
more than 200 mL of blood. Complete resection was achieved in 41 patients (93.2%). Only
one patient (2.3%) with intraoperative bleeding stayed in the intensive care unit for 1 day,
and the median postoperative hospital stay was 5 days (range: 3–32 days). The following
complications were observed in 15 patients (34.1%): prolonged air leakages (n = 5, 11.4%),
chyle leakages (n = 3, 6.8%), vocal cord palsies (n = 2, 4.5%), bronchopleural fistula (n = 1,
2.3%), acute kidney injury (n = 1, 2.3%), acute lung injury (n = 1, 2.3%), pneumonia (n = 1,
2.3%), and pneumothorax (n = 1, 2.3%). There were four complications (9.1%) of Clavien–
Dindo classification grade 3 that required additional procedures. Operative mortality
was absent.
3.3. Pathologic Analysis of Surgical Specimens
Pathologic analyses and the postoperative disease status are described in Table 4.
Twenty-three patients (52.3%) achieved radiologic no-evidence-of-disease status after
surgery. Furthermore, 10 patients (22.7%) achieved MPR, including 5 patients CR (11.4%),
at the primary site regardless of the mutation or treatment regimen. Among the 32 patients
with EGFR mutations, seven (21.9%) achieved MPR. Among the 11 patients with ALK
fusions, MPR was observed in seven patients (63.7%), including four patients (36.4%) with
complete pathologic response. The one patient (100%) with ROS1 fusion showed complete
pathologic response at the primary lesion.
Table 4. Pathology and postoperative disease status.







Primary site pathologic response
CR 5 11.4%
Major pathologic response (≤10%) 10 22.7%











Additional mutations in surgical specimens 12 27.3%
T790M 11 25.0%
MET+ 1 2.3%
Targeted agent change based on additional mutations in surgical specimens 9 20.5%
Postoperative disease status
Radiologic “no-evidence-of-disease” status 23 52.3%
Radiologic residual disease 21 47.7%
3.4. NGS and Mutation Profiles
We conducted NGS and PCR mainly in the surgical tumor samples from EGFR-mutant
patients (Figure 2); their mutation profile changes are shown in Figure 3.
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Figure 2. Landscape of mutation profiles and pathological responses at the primary lesion. (A) Land-
scape of mutation profiles analyzed using next-generation sequenci g of samples from the 32 patients
with EGFR mutations. T X-axis represents individual samples, and the Y-axis represents individual
mutated genes. The bar graph on the right shows the mutation frequency of each mutated gene in
the 32 samples. The top column represents tumor mutation burden. Different colors and notes at the
left represent mutation types. Middle rows indicate sex, smoking status, EGFR mutation subtype,
presence of the T790M mutation before surgery, targeted agent immediately before surgery, and
best response after using the targeted agent immediately before surgery. The Waterfall chart at the
bottom shows the pathologic response at the primary lesion of the 32 patients with EGFR mutations.
(B) The Waterfall chart shows the pathologic response at the primary lesion of the 12 patients with
ALK or ROS1 fusions. Upper rows indicate sex, smoking status, genetic alteration, targeted agent
immediately before surgery, and best response after using the targeted agent immediately before
surgery. RECIST: Response Evaluation Criteria in Solid Tumors.
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Figure 3. Mutation profile changes.
Among the 18 patients with sensitizing EGFR mutations treated with first- or second-
generation EGFR-TKIs, 11 patients (61.1%) developed the T790M mutation, and four
samples exhibited a discrepancy between PCR and NGS results (in three cases, T790M
mutation was revealed by PCR only and in one case, it was reported by NGS only). Nine out
of 11 patients with T790M mutations were switched to o imertinib either immediately aft r
surg ry (n = 3) or when radiol gic disea e progression became evident (n = 6). Out of
the six patients treated with second-line osimertinib before surgery based on the acquired
T790M mutation in preoperative additional biopsy mutation analysis results, three lost their
T790M mutation and one developed the EGFR C797G mutation. In addition, five had TP53
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and RB1 mutations at the time of surgery. Among them, one patient (P3) experienced SCLC
transformation 1 year after the surgery; he had TP53 c.2369C>T (or p.V173M) mutation
and RB1 c.1332+1G>C mutation (splice variant at protein level). Another patient (P16)
experienced the same event 2 years after the surgery; he retained a TP53 indel mutation
(p.MG243IC) and an RB1 frameshift mutation (p.V654fs*4).
3.5. Survival Analysis
The median follow-up period after the initiation of TKI therapy immediately before the
surgery and the postoperative follow-up period were 23.1 months (range: 4.8–41.8 months)
and 12.0 months (range: 2.6–32.9 months) months, respectively. The Kaplan–Meier survival
analysis showed that the 2-year FFS and OS rates from the initiation of TKI immediately before
the surgery were 70.8% and 95.0%, respectively (Figure 4A,B). In patients with EGFR mutations,
these parameters were 58.5% and 93.0%, respectively, and they were 100.0% in patients with
ALK and ROS1 fusions. The 1-year PFS and OS rates from the operation were 64.8% and
94.8%, respectively (Figure 4C,D). The Kaplan–Meier survival curves according to the intent of
surgery and pathological response at the primary lesion are shown in Figure 5.
During the follow-up periods, 15 patients experienced disease progression in the
lung (n = 6), brain (n = 4), bone (n = 2), pleura (n = 1), and other sites (n = 2). Two pa-
tients died during the follow-up period, one patient died 7.9 months postoperatively
because of cancer progression, and one other patient died of acute coronary syndrome at
2.6 months postoperatively.
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4. Discussion 
The initial systemic therapy may lead to stable or responsive disease, but the remain-
ing tumors may contain treatment-resistant malignant cells that are not eliminated by the 
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4. iscussion
he initial syste ic therapy ay lead to stable or responsive disease, but the remaining
tumors may contain treatment-resistant malignant cells that are not eli inated by the
aintenance therapy. These re aining drug-tolerant persistent tu ors ay cause the
subsequent etastatic spread even if they do not have radiographic progression [16].
Therefore, local consolidative treatment may delay clinical disease progression and improve
prognosis by removing such drug-tolerant persister cells. However, radiation therapy has
predominantly been used as a local consolidative treatment in the published trials [6–9].
A recent study in patients with advanced EGFR-mutant NSCLC reported that TKIs plus
thoracic stereotactic body radiation therapy (SBRT) significantly extends PFS with tolerable
toxicity [17]. They reported median PFS was 19.4 months in the TKIs plus SBRT group.
Our group has conducted surgical resection as a local consolidative treatment in advanced
NSCLC with driver mutations. In the present study of a limited set of patients with
relatively short follow-up periods, the 2-year FFS and OS rates were 70.8% and 95.0%,
respectively, whereas median OS and FFS had not yet been reached. Although it is difficult
to directly compare our results to the previous reports, our findings show a promising
prognosis with tolerable surgical morbidity and tumor samples for genetic analysis. The
rationale for pulmonary resection and its benefits over consolidative radiotherapy is as
follows: (1) TKI-treated patients ultimately develop resistance to the drugs, a condition
for which there is no established treatment; (2) primary lung lesion is the most common
resistant site; (3) surgery is the most reliable method of tumor removal that enables accurate
staging and treatment through mediastinal lymph node dissection; and (4) surgical tumor
samples provide information about tumor heterogeneity and mutational evolution to guide
subsequent treatment. Surgical outcomes after TKI use in advanced NSCLC with driver
mutation have been reported for a small group of patients [18]. This retrospective study
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for the first time reports the operative outcomes and the benefit of cytoreductive surgery in
TKI-treated cases of oncogene-driven locally advanced or metastatic NSCLC in parallel
with the genetic analysis of the tumor.
Our analysis of the surgical outcomes after TKI therapy demonstrated that surgical
intervention was feasible and safe; operative mortality was absent and operative morbidi-
ties were observed only in 15 cases (34.1%). The four complications (9.1%) above grade 3
were chylothorax, vocal cord palsy, bronchopleural fistula, and delayed pneumothorax.
Minimally invasive resection was carried out in 37 patients (84.1%). The conversion rate to
the open thoracotomy occurred in five patients (11.4%). In most patients, it was difficult
to dissect the lymph node and the bronchus or pulmonary artery, and two patients had
bleeding because of pulmonary artery injury. Owing to the response of cancer cells to the
TKI, previously metastatic lymph nodes became fibrotic, which complicated the operation
technically, especially around the pulmonary artery (Figure 6). Our conversion rate was
higher than the thoracotomy conversion rate in simple VATS lobectomy in NSCLC [19],
but it is acceptable when compared to the results in another neoadjuvant series [20]. Op-
erational time, blood loss, and hospital stay were longer than those in simple pulmonary
resection, but generally acceptable. We did not stop TKI therapy during the perioperative
periods, in contrast to what is usually done for cytotoxic chemotherapy agents. There
is no reason to believe that TKI therapy itself caused any of the observed complications.
Another advantage of surgical resection was the possibility to examine the thoracic cavity.
For example, pleural seeding, which was not noticed at the preoperative imaging, was thus
observed in two patients.
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helps in establishing further treat ent plans. ong the 44 patients, five (11.4 ) sho ed
a co plete response and 10 (22.7%) showed MPR at the primary lesion. As the initial
tumor stages were mostly stage IV or late stage III, TKI therapy was continued even in
patients who showed complete response. Even though there have been no recurrences
in the patients who had a complete response in the set follow-up periods, whether com-
plete response or MPR correlated with improved survival has to be established by the
longer follow-up. It has been reported that EGFR-TKIs are cytostatic rather than cytotoxic
agents, which do not eradicate micrometastatic tumor cells even after a marked clinical
response [21]. Interestingly, all our patients who showed the complete response at the
primary and metastatic lesions had ALK rearrangement. This suggests that NSCLC with
ALK fusion is relatively homogenous and may display features of oncogene addiction,
which, in turn, may explain higher median survival of patients with ALK fusions treated
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with ALK-TKIs compared to that of patients with EGFR mutations treated with EGFR-
TKIs [8,22]. These findings warrant further studies of the biomarkers of complete response
to ALK inhibitors.
Mechanisms of acquired resistance to front-line and later-line osimertinib are similar,
except the absence of the T790M mutation after the former regimen [23]. In line with
previous reports [24], we observed that half of the patients with the EGFR T790M mutation
lost it after later-line osimertinib treatment. We also observed inconsistent PCR and
NGS results, which may reflect the difference in the performance of the testing method
and/or tumor heterogeneity. Considering that NGS sensitivity is higher than that of
PCR in general, and that one and three patients were found to have T790M mutation
only using NGS and only using PCR, respectively, this discrepancy was likely because
of tumor heterogeneity. Our data showed the trend that patients with EGFR mutations
that harbored fewer concurrent mutations had better response to EGFR-TKIs (Figure 2A),
which was consistent with the recent reports [25–27]. The objective response rate in patients
without concomitant mutations was significantly higher (77% vs. 44%) [25]. In addition,
the mutational analysis of postoperative tumor tissue may reveal acquired resistance
mechanisms and guide subsequent treatment, as was demonstrated in our data set. Nine
patients had started osimertinib because of the revealed EGFR T790M mutation, and two
patients were enrolled in an MET inhibitor trial based on the presence of MET amplification.
The occurrence of TP53 and RB1 mutations during the EGFR-TKI treatment predicted SCLC
transformation in two patients. The inactivating TP53 and RB1 mutations were detected
1 or 2 years before clinical progression, which supported the notion that EGFR-TKI-resistant
SCLC cells branches out at the early stage from the adenocarcinoma clones [28].
Regarding the diagnostic accuracy, the methods that we used do not capture every
oncogenic alteration in EGFR mutation and ROS1 fusion. However, detecting EGFR
mutations, the PANAMutyper assay can capture sensitizing mutations (19del and L858R),
resistant mutation (T790M) and major uncommon EGFR mutations (S768I, G719X, and
L861Q), and is highly concordant to the Roche cobas® EGFR version 2, which is approved
by the U.S. Food and Drug Administration [29]. In addition, ROS1 fusion genes detectable
by the AmoyDx ROS1 Gene Fusions Detection Kit account for approximately 83% of all
ROS1 gene fusions [30]. However, considering that all of the patients in the study had
oncogenic genetic alteration at baseline, the analytical sensitivity of the PCR-based test can
be said to be 100% based on the oncogenic (driver) mutation in the preoperative sample.
This study had some limitations. First, it was a single-center retrospective study with
few patients. Second, NGS data from the tissue before TKI treatment were not available;
therefore, whether the revealed genetic alterations had been already present at baseline
remained unknown. Third, we did not perform a liquid biopsy before and after the TKIs.
If performed, it could help to capture tumor heterogeneity. Lastly, the effects of surgery on
OS must be evaluated with longer follow-up periods and further prospective clinical trials.
Despite these limitations, this study is valuable, as it is the first report on the outcomes
and pathologic results of cytoreductive surgery in patients with oncogene-driven locally
advanced or metastatic NSCLC. Many questions, such as operation timing (early vs. late
operation), selection of the proper indication, including the suitable biomarker, extent of
surgical resection (anatomic resection vs. sub-lobar resection), and continuation of TKI,
remain to be resolved in further studies.
5. Conclusions
In conclusion, pulmonary resection for advanced NSCLC after targeted therapy is
feasible, and the surgical specimens obtained could be used for further planning of targeted
therapy. The long-term benefits of pulmonary resection on survival after targeted therapy
must be studied in future trials.
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